FindTrial
Sign In

Efficacy of rTMS in the Treatment of Patients With Migraine

Therapeutic Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Migraine Using Somatosensory Evoked High-Frequency Oscillations as a Parameter: A 3-year Study.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00316979
Enrollment
80
Registered
2006-04-21
Start date
2006-04-30
Completion date
Unknown
Last updated
2010-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Keywords

migraine, transcranial magnetic stimulation, repetitive transcranial magnetic stimulation, rTMS

Brief summary

Migraine is a condition thought to be related to cortical hyperexcitability. Repetitive transcranial magnetic stimulation (rTMS) can modulate the cortical excitability by means of long-term potentiation or long-term depression. This study will will test the safety and efficacy of rTMS in the treatment of patients with Migraine.

Interventions

DEVICERepetitive Transcranial Magnetic Stimulation (rTMS)

Sponsors

National Science and Technology Council, Taiwan
CollaboratorOTHER_GOV
Taipei Veterans General Hospital, Taiwan
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Age of 18-65 years * Diagnosed as migraine (with or without aura) * More than 4 attacks per month for at least 3 months prior to study * No preventive medication used * Must be able to sign permit

Exclusion criteria

* History of seizure or family history of seizures * Women in pregnancy or breast-feeding * Patient with medication overuse * Patient with other medical, psychologic, or surgical illness * Patient under preventive medications * Prior rTMS examination one month within

Design outcomes

Primary

MeasureTime frame
Reduction in days of migraine attack per month—

Secondary

MeasureTime frame
The reduction in dosage of acute abortive medication—
The reduction of headache index—

Countries

Taiwan

Contacts

Primary ContactShuu-Jiun Wang, MD
sjwang@vghtpe.gov.tw+886-2-28712121
Backup ContactKuan-Lin Lai, MD
kllai@vghtpe.gov.tw+886-2-28712121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026